Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves.

Vaccine
W Ray WatersWilliam R Jacobs

Abstract

An attenuated Mycobacterium bovisRD1 deletion (DeltaRD1) mutant of the Ravenel strain was constructed, characterized, and sequenced. This M. bovis DeltaRD1 vaccine strain administered to calves at 2 weeks of age provided similar efficacy as M. bovis bacillus Calmette Guerin (BCG) against low dose, aerosol challenge with virulent M. bovis at 3.5 months of age. Approximately 4.5 months after challenge, both DeltaRD1- and BCG-vaccinates had reduced tuberculosis (TB)-associated pathology in lungs and lung-associated lymph nodes and M. bovis colonization of tracheobronchial lymph nodes as compared to non-vaccinates. Mean central memory responses elicited by either DeltaRD1 or BCG prior to challenge correlated with reduced pathology and bacterial colonization. Neither DeltaRD1 or BCG elicited IFN-gamma responses to rESAT-6:CFP-10 prior to challenge, an emerging tool for modern TB surveillance programs. The DeltaRD1 strain may prove useful for bovine TB vaccine programs, particularly if additional mutations are included to improve safety and immunogenicity.

References

Sep 1, 1997·Nucleic Acids Research·S F AltschulD J Lipman
Dec 10, 1997·Journal of Wildlife Diseases·S M SchmittJ Sikarskie
Sep 29, 2000·Lancet·P AndersenT M Doherty
May 1, 2001·Clinical and Diagnostic Laboratory Immunology·H M VordermeierR G Hewinson
Jul 21, 2001·Tuberculosis·B M Buddle
Dec 24, 2002·Infection and Immunity·W R WatersD L Whipple
Apr 15, 2003·Nature Medicine·Alexander S PymStewart T Cole
Jun 6, 2003·Proceedings of the National Academy of Sciences of the United States of America·Thierry GarnierR Glyn Hewinson
Oct 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Tsungda HsuWilliam R Jacobs
Jan 22, 2004·Journal of Wildlife Diseases·Mitchell V PalmerDiana L Whipple
May 26, 2005·Microbes and Infection·Vasan K Sambandamurthy, William R Jacobs
Dec 24, 2005·Expert Review of Vaccines·Jayne C Hope, H Martin Vordermeier
May 10, 2006·Veterinary Immunology and Immunopathology·Martin Vordermeier, R Glyn Hewinson
Mar 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Roland BroschStewart T Cole
Jun 5, 2007·Expert Review of Vaccines·Martin L Cross, Frank Aldwell
Jul 31, 2007·PLoS Pathogens·Kamalakannan VelmuruganVolker Briken
Aug 3, 2007·The Journal of Clinical Investigation·Joseph HincheySteven A Porcelli
Jan 30, 2008·Bioinformatics·Ruiqiang LiJun Wang

❮ Previous
Next ❯

Citations

Nov 26, 2013·The Lancet Infectious Diseases·Marcel A Behr, W Ray Waters
Apr 16, 2014·Research in Veterinary Science·M DomingoA Marco
Jun 3, 2009·Infection and Immunity·H Martin VordermeierR Glyn Hewinson
Dec 3, 2010·Proceedings. Biological Sciences·Mark A ChambersR Glyn Hewinson
Jun 29, 2011·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
Feb 18, 2016·Annual Review of Animal Biosciences·H Martin VordermeierBernardo Villarreal-Ramos
Aug 3, 2011·Expert Review of Vaccines·Martin VordermeierAdam O Whelan
Feb 26, 2016·Veterinary Immunology and Immunopathology·H Martin VordermeierR Glyn Hewinson
Dec 15, 2012·Vaccine·Benoît LevastVolker Gerdts
Mar 23, 2011·Veterinary Microbiology·Bryce M BuddleR Glyn Hewinson
Aug 28, 2012·Comparative Immunology, Microbiology and Infectious Diseases·Paul D van Helden, Eileen G Hoal
Nov 6, 2013·Transboundary and Emerging Diseases·B M BuddleA Heiser
Jan 5, 2011·Clinical & Developmental Immunology·W Ray WatersD Mark Estes
Jan 8, 2014·Vaccine·Bhagwati KhatriH Martin Vordermeier
Feb 22, 2012·Vaccine·W Ray WatersH Martin Vordermeier
Mar 4, 2015·Proceedings of the National Academy of Sciences of the United States of America·Haibo WuYong Zhang
Aug 19, 2016·PLoS Neglected Tropical Diseases·Aseem PandeyPaul de Figueiredo
Sep 6, 2012·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·I P Nascimento, L C C Leite
Mar 8, 2012·The Journal of Infectious Diseases·Angela M MinassianHelen McShane
Dec 18, 2015·Clinical and Vaccine Immunology : CVI·W Ray WatersMichelle H Larsen
Jul 31, 2009·Clinical and Vaccine Immunology : CVI·H Martin VordermeierPhilip J Hogarth
Nov 7, 2019·Scientific Reports·Mariana Guerra-Maupome, Jodi L McGill
Feb 18, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jodi L McGillW Ray Waters
May 25, 2021·Frontiers in Veterinary Science·Mitchell V PalmerPaola M Boggiatto
Oct 12, 2016·Microbiology Spectrum·Bryce M BuddleR Glyn Hewinson
Jun 18, 2021·Microbiology Resource Announcements·Syeda A HadiSrinand Sreevatsan
Aug 3, 2021·Frontiers in Veterinary Science·Paola M BoggiattoMitchell V Palmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.